Fellow Longs (KEEP IN MIND) 2 potential other CNS indications (1) Autism & (2) Speech & Swallowing in ALS
Building... a leading CNS platform
Throughout fiscal 2012, we saw steady pipeline progress, including data presentations, regulatory submissions and clinical trial initiations.
We have a number of potential indications that we believe our CNS platform can address. The results from the trials in the following areas are expected to be near- and mid-term catalysts for our business.
Agitation in Alzheimer's disease
Central neuropathic pain in multiple sclerosis
Levodopa induced dyskinesia in Parkinson's disease
Speech & Swallowing in ALS
Please keep in mind that agitation -in -dementia, levodopa- induced- dyskinesia, autism and speech and swallowing, are, theoretical uses for dex/quin, are in embryonic stages of research with low quality bases for clilnical study and are unlikely to be proven to be effective.
Ray, "ineffective!" Gee thanks you mad scientist! If you think Nuedexta will be ineffective in treating "agitation -in -dementia, levodopa- induced- dyskinesia, autism and speech and swallowing" you might want to increase your Short Interest position! Ray, you never did share with all your fans where you received your medical degree! Cheers doctor Ray!